- Home
- RCEL vs DSM Comparison
RCEL vs DSM Comparison
Compare RCEL & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- DSM
- Stock Information
- Founded
- RCEL N/A
- DSM 1989
- Country
- RCEL United States
- DSM United States
- Employees
- RCEL N/A
- DSM N/A
- Industry
- RCEL Medical/Dental Instruments
- DSM Investment Managers
- Sector
- RCEL Health Care
- DSM Finance
- Exchange
- RCEL Nasdaq
- DSM Nasdaq
- Market Cap
- RCEL 227.5M
- DSM 270.9M
- IPO Year
- RCEL N/A
- DSM N/A
- Fundamental
- Price
- RCEL $9.21
- DSM $5.51
- Analyst Decision
- RCEL Strong Buy
- DSM
- Analyst Count
- RCEL 4
- DSM 0
- Target Price
- RCEL $17.25
- DSM N/A
- AVG Volume (30 Days)
- RCEL 201.7K
- DSM 161.7K
- Earning Date
- RCEL 05-08-2025
- DSM 01-01-0001
- Dividend Yield
- RCEL N/A
- DSM 3.97%
- EPS Growth
- RCEL N/A
- DSM N/A
- EPS
- RCEL N/A
- DSM N/A
- Revenue
- RCEL $64,251,000.00
- DSM N/A
- Revenue This Year
- RCEL $62.33
- DSM N/A
- Revenue Next Year
- RCEL $30.59
- DSM N/A
- P/E Ratio
- RCEL N/A
- DSM N/A
- Revenue Growth
- RCEL 28.14
- DSM N/A
- 52 Week Low
- RCEL $6.90
- DSM $4.69
- 52 Week High
- RCEL $14.16
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- RCEL 56.76
- DSM 37.11
- Support Level
- RCEL $8.15
- DSM $5.28
- Resistance Level
- RCEL $9.36
- DSM $5.77
- Average True Range (ATR)
- RCEL 0.67
- DSM 0.10
- MACD
- RCEL 0.15
- DSM -0.02
- Stochastic Oscillator
- RCEL 93.90
- DSM 37.70
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.